<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Aluminum hydroxide, magnesium hydroxide, and simethicone: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Aluminum hydroxide, magnesium hydroxide, and simethicone: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Aluminum hydroxide, magnesium hydroxide, and simethicone: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11060" href="/d/html/11060.html" rel="external">see "Aluminum hydroxide, magnesium hydroxide, and simethicone: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="135268" href="/d/html/135268.html" rel="external">see "Aluminum hydroxide, magnesium hydroxide, and simethicone: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F132556"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Almacone Double Strength [OTC];</li>
<li>Almacone [OTC] [DSC];</li>
<li>Alumina-Magnesia-Simethicone [OTC] [DSC];</li>
<li>Antacid Anti-Gas Max Strength [OTC];</li>
<li>Antacid Anti-Gas [OTC];</li>
<li>Antacid Extra Strength [OTC];</li>
<li>Antacid Fast Relief [OTC];</li>
<li>Antacid I [OTC];</li>
<li>Antacid III [OTC];</li>
<li>Antacid Plus Anti-Gas Relief [OTC] [DSC];</li>
<li>Antacid Regular Strength [OTC];</li>
<li>Antacid [OTC] [DSC];</li>
<li>Antacid/Anti-Gas [OTC] [DSC];</li>
<li>Antacid/Antigas [OTC];</li>
<li>FT Antacid &amp; Antigas [OTC];</li>
<li>Gelusil [OTC];</li>
<li>Geri-Lanta Maximum Strength [OTC];</li>
<li>Geri-Lanta [OTC];</li>
<li>Geri-Mox [OTC];</li>
<li>GoodSense Advanced Antacid [OTC];</li>
<li>GoodSense Antacid &amp; Gas Relief [OTC];</li>
<li>HyVee Advanced Antacid [OTC];</li>
<li>Maalox Max [OTC];</li>
<li>Maalox Multi Symptom Max St [OTC];</li>
<li>Mag-Al Plus XS [OTC];</li>
<li>Mag-Al Plus [OTC];</li>
<li>Mi-Acid Maximum Strength [OTC] [DSC];</li>
<li>Mi-Acid [OTC] [DSC];</li>
<li>Milantex Extra Strength [OTC] [DSC];</li>
<li>Milantex [OTC] [DSC];</li>
<li>Mintox Maximum Strength [OTC];</li>
<li>Mintox Plus [OTC];</li>
<li>Mintox Regular Strength [OTC] [DSC];</li>
<li>Mylanta Maximum Strength [OTC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F132567"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antacid;</li>
<li>
                        Antiflatulent</li></ul></div>
<div class="block doa drugH1Div" id="F132559"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0b252c65-f530-4a8d-9101-a641d7464f9c">Antacid/antigas</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Antacid/antigas:</b> Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Products containing aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 25 mg per tablet: 1 to 4 tablets 4 times daily; may also take as needed, up to 12 to 16 tablets/24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Products containing aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 20 mg per 5 mL: 10 to 20 mL between meals, at bedtime, or as directed by health care provider; maximum: 120 mL/24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Products containing aluminum hydroxide 400 mg, magnesium hydroxide 400 mg, and simethicone 40 mg per 5 mL: 10 to 20 mL between meals, at bedtime, or as directed by health care provider; maximum: 40 to 60 mL/24 hours.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F53006097"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; aluminum and/or magnesium may accumulate in renal impairment.</p></div>
<div class="block doha drugH1Div" id="F53006098"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F132560"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F26319868"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="135268" href="/d/html/135268.html" rel="external">see "Aluminum hydroxide, magnesium hydroxide, and simethicone: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Chronic antacid therapy not recommended for management of gastroesophageal reflux disease (GERD) in pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23629618','lexi-content-ref-29470322']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23629618','lexi-content-ref-29470322'])">Ref</a></span>). Multiple concentrations of liquid dosage forms exist; close attention must be paid to the concentration when ordering or administering. Approved ages and uses for products may vary; consult product labeling for specific information.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="71a34ac3-0815-4647-9331-d6e21ef084a2">Heartburn/Indigestion</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heartburn/Indigestion:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Liquid: Children ≥12 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 20 mg per 5 mL (eg, Mi-Acid, Mag Al Plus): Oral: 10 to 20 mL 4 times daily as needed between meals and at bedtime, or as directed by a health care provider; maximum daily dose: 120 mL per 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Aluminum hydroxide 400 mg, magnesium hydroxide 400 mg, and simethicone 40 mg per 5 mL (eg, Mi-Acid Maximum): Oral: 10 to 20 mL 4 times daily as needed between meals and at bedtime, or as directed by a health care provider; maximum daily dose: 60 mL per 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet, chewable: Children ≥12 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 25 mg per tablet (eg, Gelusil, Mintox Plus): Oral: 2 to 4 tablets; may repeat hourly as needed; maximum daily dose: 12 tablets per 24 hours.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F56680701"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; aluminum and/or magnesium may accumulate in renal impairment; avoid use due to risk of aluminum toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29470322']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29470322'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F56680702"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F132543"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">&gt;10%: Gastrointestinal: Constipation, decreased gastrointestinal motility, fecal impaction, hemorrhoids, stomach cramps, unpleasant taste (chalky)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">1% to 10%: Gastrointestinal: Fecal discoloration (white speckles), nausea, vomiting </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">&lt;1%, postmarketing, and/or case reports: Dehydration, fluid retention, hypomagnesemia, hypophosphatemia</p></div>
<div class="block coi drugH1Div" id="F26319854"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">OTC labeling: When used for self-medication, do not use if you have kidney disease; do not use more than the recommended dose for more than 2 weeks.</p></div>
<div class="block war drugH1Div" id="F26319855"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypophosphatemia: Prolonged antacid therapy may result in hypophosphatemia; aluminum in antacid may form insoluble complexes with phosphate leading to decreased phosphate absorption in the GI tract. Rarely, severe hypophosphatemia can lead to anorexia, muscle weakness, malaise, and osteomalacia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Hypermagnesemia or aluminum intoxication may occur in patients with renal impairment, particularly with prolonged use. Aluminum intoxication may lead to osteomalacia or dialysis encephalopathy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Phenylalanine: Some products may contain phenylalanine.</p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP ["Inactive" 1997]; Zar 2007).</p>
<p style="text-indent:-2em;margin-left:4em;">• Sodium: Some products may contain sodium.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Self-medication (OTC use): When used for self-medication, patients should be instructed to consult their health care prescriber prior to using if they are on a magnesium- and/or sodium-restricted diet. Do not take the maximum dose for &gt;14 days.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F56680698"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Absorption of aluminum has been reported in infants receiving both short-term and long-term antacid therapy (Tsou 1991; Woodard-Knight 1992); use of aluminum antacids is not recommended in infants or in pediatric patients with kidney impairment (NASPGHAN/ESPGHAN [Rosen 2018]).</p>
<p style="text-indent:0em;margin-top:2em;">Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults, including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F132548"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Liquid, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mag-Al Plus: Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 20 mg per 5 mL (30 mL) [sugar free; contains butylparaben, propylene glycol, propylparaben, saccharin sodium; peppermint flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mag-Al Plus XS: Aluminum hydroxide 400 mg, magnesium hydroxide 400 mg, and simethicone 40 mg per 5 mL (30 mL) [sugar free; contains butylparaben, propylene glycol, propylparaben, saccharin sodium; cherry flavor]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Almacone: Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 20 mg per 5 mL (355 mL [DSC]) [gluten free, low sodium; contains butylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Almacone Double Strength: Aluminum hydroxide 400 mg, magnesium hydroxide 400 mg, and simethicone 40 mg per 5 mL (355 mL) [contains alcohol, usp, benzyl alcohol, butylparaben, propylparaben, saccharin sodium; mint flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Alumina-Magnesia-Simethicone: Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 20 mg per 5 mL (30 mL [DSC]) [contains butylparaben, propylparaben, saccharin sodium; lemon-mint flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Antacid: Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 20 mg per 5 mL (355 mL [DSC]); Aluminum hydroxide 400 mg, magnesium hydroxide 400 mg, and simethicone 40 mg per 5 mL (355 mL [DSC]) [sodium free; contains parabens, saccharin]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Antacid Anti-Gas: Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 20 mg per 5 mL (355 mL) [contains saccharin]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Antacid Anti-Gas Max Strength: Aluminum hydroxide 400 mg, magnesium hydroxide 400 mg, and simethicone 40 mg per 5 mL (355 mL) [contains butylparaben, propylparaben, sorbitol; lemon flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Antacid Extra Strength: Aluminum hydroxide 400 mg, magnesium hydroxide 400 mg, and simethicone 40 mg per 5 mL (355 mL) [contains saccharin]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Antacid Fast Relief: Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 20 mg per 5 mL (355 mL) [contains parabens, saccharin]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Antacid I: Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 20 mg per 5 mL (360 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Antacid III: Aluminum hydroxide 400 mg, magnesium hydroxide 400 mg, and simethicone 40 mg per 5 mL (360 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Antacid Plus Anti-Gas Relief: Aluminum hydroxide 400 mg, magnesium hydroxide 400 mg, and simethicone 40 mg per 5 mL (355 mL [DSC]) [contains butylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Antacid Regular Strength: Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 20 mg per 5 mL (355 mL) [contains alcohol, usp, methylparaben, propylene glycol, propylparaben, saccharin sodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Antacid Regular Strength: Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 20 mg per 5 mL (30 mL) [contains parabens, saccharin]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Antacid/Anti-Gas: Aluminum hydroxide 400 mg, magnesium hydroxide 400 mg, and simethicone 40 mg per 5 mL (355 mL [DSC]) [contains alcohol, usp, benzyl alcohol, butylparaben, propylparaben, saccharin sodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Antacid/Antigas: Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 20 mg per 5 mL (355 mL) [contains butylparaben, propylparaben, saccharin sodium; cool mint flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT Antacid &amp; Antigas: Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 20 mg per 5 mL (355 mL); Aluminum hydroxide 400 mg, magnesium hydroxide 400 mg, and simethicone 40 mg per 5 mL (355 mL) [contains alcohol, usp, benzyl alcohol, butylparaben, propylparaben, saccharin sodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT Antacid &amp; Antigas: Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 20 mg per 5 mL (355 mL); Aluminum hydroxide 400 mg, magnesium hydroxide 400 mg, and simethicone 40 mg per 5 mL (355 mL) [contains benzyl alcohol, butylparaben, propylparaben, saccharin sodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Geri-Lanta: Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 20 mg per 5 mL (355 mL) [contains benzyl alcohol, butylparaben, propylparaben, saccharin sodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Geri-Lanta Maximum Strength: Aluminum hydroxide 400 mg, magnesium hydroxide 400 mg, and simethicone 40 mg per 5 mL (355 mL) [contains alcohol, usp, benzyl alcohol, butylparaben, propylparaben, saccharin sodium; lemon flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Geri-Mox: Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 20 mg per 5 mL (769 mL [DSC]) [contains benzyl alcohol, butylparaben, propylparaben, saccharin sodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Geri-Mox: Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 20 mg per 5 mL (355 mL) [contains benzyl alcohol, butylparaben, propylparaben, saccharin sodium; mint flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">GoodSense Advanced Antacid: Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 20 mg per 5 mL (355 mL) [contains benzyl alcohol, butylparaben, propylparaben, saccharin sodium; cool mint flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">GoodSense Antacid &amp; Gas Relief: Aluminum hydroxide 400 mg, magnesium hydroxide 400 mg, and simethicone 40 mg per 5 mL (355 mL) [contains alcohol, usp, benzyl alcohol, butylparaben, propylparaben, saccharin sodium; original flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">GoodSense Antacid &amp; Gas Relief: Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 20 mg per 5 mL (355 mL) [contains alcohol, usp, butylparaben, propylparaben, saccharin sodium; original flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">GoodSense Antacid &amp; Gas Relief: Aluminum hydroxide 400 mg, magnesium hydroxide 400 mg, and simethicone 40 mg per 5 mL (355 mL) [contains butylparaben, propylparaben, saccharin sodium; cherry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">HyVee Advanced Antacid: Aluminum hydroxide 400 mg, magnesium hydroxide 400 mg, and simethicone 40 mg per 5 mL (355 mL) [gluten free; contains butylparaben, propylene glycol, propylparaben, saccharin sodium; cherry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Maalox Max: Aluminum hydroxide 400 mg, magnesium hydroxide 400 mg, and simethicone 40 mg per 5 mL (355 mL) [contains propylparaben, quinoline yellow (d&amp;c yellow #10), saccharin sodium; lemon flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Maalox Max: Aluminum hydroxide 400 mg, magnesium hydroxide 400 mg, and simethicone 40 mg per 5 mL (355 mL) [contains propylparaben, saccharin sodium; cherry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Maalox Max: Aluminum hydroxide 400 mg, magnesium hydroxide 400 mg, and simethicone 40 mg per 5 mL (355 mL) [contains propylparaben, saccharin sodium; wild berry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Maalox Multi Symptom Max St: Aluminum hydroxide 400 mg, magnesium hydroxide 400 mg, and simethicone 40 mg per 5 mL (769 mL) [contains butylparaben, propylene glycol, propylparaben, saccharin sodium; wild berry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mi-Acid: Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 20 mg per 5 mL (355 mL [DSC]) [contains butylparaben, propylparaben, saccharin sodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mi-Acid: Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 20 mg per 5 mL (355 mL [DSC]) [gluten free; contains alcohol, usp, butylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mi-Acid Maximum Strength: Aluminum hydroxide 400 mg, magnesium hydroxide 400 mg, and simethicone 40 mg per 5 mL (355 mL [DSC]) [gluten free; contains butylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Milantex: Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 20 mg per 5 mL (355 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Milantex Extra Strength: Aluminum hydroxide 400 mg, magnesium hydroxide 400 mg, and simethicone 40 mg per 5 mL (355 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mintox Maximum Strength: Aluminum hydroxide 400 mg, magnesium hydroxide 400 mg, and simethicone 40 mg per 5 mL (355 mL) [contains butylparaben, propylparaben, quinoline yellow (d&amp;c yellow #10), saccharin sodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mintox Regular Strength: Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 20 mg per 5 mL (355 mL [DSC]) [contains butylparaben, propylparaben, saccharin sodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mylanta Maximum Strength: Aluminum hydroxide 400 mg, magnesium hydroxide 400 mg, and simethicone 40 mg per 5 mL (355 mL) [paraben free; vanilla caramel flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 20 mg per 5 mL (30 mL); Aluminum hydroxide 400 mg, magnesium hydroxide 400 mg, and simethicone 40 mg per 5 mL (30 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Chewable, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gelusil: Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 25 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mintox Plus: Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and simethicone 25 mg [lemon-mint flavor]</p></div>
<div class="block geq drugH1Div" id="F132538"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F16322977"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Chewable</b> (Gelusil Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200-200-25 mg (per each): $0.04</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Chewable</b> (Mintox Plus Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200-200-25 mg (per each): $0.05</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Almacone Double Strength Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400-400-40 mg/5 mL (per mL): $0.01</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Maalox Max Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400-400-40 mg/5 mL (per mL): $0.02</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Maalox Multi Symptom Max St Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400-400-40 mg/5 mL (per mL): $0.01</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F132550"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Administer 1 hour after meals or between meals.</p>
<p style="text-indent:-2em;margin-left:2em;">Suspension: Shake well prior to use.</p></div>
<div class="block admp drugH1Div" id="F52612211"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer between meals or at bedtime.</p>
<p style="text-indent:-2em;margin-left:2em;">Suspension: Shake well prior to use.</p></div>
<div class="block use drugH1Div" id="F132549"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Antacid/antigas:</b> Relief of acid indigestion, heartburn, sour stomach, or upset stomach and gas associated with these symptoms</p></div>
<div class="block mst drugH1Div" id="F132571"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Maalox may be confused with Maox, Monodox</p>
<p style="text-indent:2em;">Maalox may be confused with other Maalox products (eg, calcium carbonate)</p>
<p style="text-indent:-2em;margin-left:4em;">Mylanta may be confused with Mynatal</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298726"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F132544"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: Antacids may decrease the serum concentration of Acalabrutinib.  Management: Separate administration of acalabrutinib capsules from the administration of any antacid by at least 2 hours in order to minimize the potential for a significant interaction. Acalabrutinib tablets are not expected to interact with antacids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfacalcidol: May increase the serum concentration of Magnesium Salts. Management: Consider using a non-magnesium-containing antacid or phosphate-binding product in patients also receiving alfacalcidol.  If magnesium-containing products must be used with alfacalcidol, serum magnesium concentrations should be monitored closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Allopurinol: Aluminum Hydroxide may decrease the serum concentration of Allopurinol.  Management: Consider administering allopurinol 3 hours prior to aluminum hydroxide.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Lipoic Acid: Magnesium Salts may decrease the absorption of Alpha-Lipoic Acid. Alpha-Lipoic Acid may decrease the absorption of Magnesium Salts.  Management: Separate administration of alpha-lipoic acid from that of any magnesium-containing compounds by several hours. If alpha-lipoic acid is given 30 minutes before breakfast, then administer oral magnesium-containing products at lunch or dinner.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Phenothiazines): Antacids may decrease the absorption of Antipsychotic Agents (Phenothiazines). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ascorbic Acid: May increase the absorption of Aluminum Hydroxide. Management: In patients with severe renal dysfunction, consider avoiding this combination. Administering agents at least 2 hours apart may help minimize effects. Monitor for toxic effects of aluminum (from antacid) if ascorbic acid is coadministered.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: Antacids may decrease the absorption of Atazanavir.  Management: Administer antacids 1 to 2 hours before or 2 hours after atazanavir to minimize the risk of a clinically significant interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baloxavir Marboxil: Polyvalent Cation Containing Products may decrease the serum concentration of Baloxavir Marboxil. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belumosudil: Antacids may decrease the serum concentration of Belumosudil.  Management: Consider separating administration of belumosudil and antacids by 2 hours and monitor for reduced belumosudil efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bictegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Bictegravir.  Management: Administer bictegravir under fasting conditions at least 2 hours before or 6 hours after polyvalent cation containing products. Coadministration of bictegravir with or 2 hours after most polyvalent cation products is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisacodyl: Antacids may diminish the therapeutic effect of Bisacodyl. Antacids may cause the delayed-release bisacodyl tablets to release drug prior to reaching the large intestine.  Gastric irritation and/or cramps may occur.  Management: Antacids should not be used within 1 hour before bisacodyl administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bismuth Subcitrate: Antacids may diminish the therapeutic effect of Bismuth Subcitrate.  Management: Avoid administration of antacids within 30 minutes of bismuth subcitrate (tripotassium bismuth dicitrate) administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisphosphonate Derivatives: Polyvalent Cation Containing Products may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral medications containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosutinib: Antacids may decrease the serum concentration of Bosutinib.  Management: Administer antacids more than 2 hours before or after bosutinib.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: Antacids may decrease the absorption of Bromperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabotegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Cabotegravir.  Management: Administer polyvalent cation containing products at least 2 hours before or 4 hours after oral cabotegravir.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcitriol (Systemic): May increase the serum concentration of Magnesium Salts. Management: Consider using a non-magnesium-containing antacid or phosphate-binding product in patients also receiving calcitriol. If magnesium-containing products must be used with calcitriol, serum magnesium concentrations should be monitored closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Polystyrene Sulfonate: Laxatives (Magnesium Containing) may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. More specifically, concomitant use of calcium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of calcium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Captopril: Antacids may decrease the serum concentration of Captopril. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefdinir: Antacids may decrease the absorption of Cefdinir.  Management: Administer cefdinir 2 hours before or 2 hours after aluminum- or magnesium-containing antacids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefditoren: Antacids may decrease the serum concentration of Cefditoren. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefpodoxime: Antacids may decrease the serum concentration of Cefpodoxime. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefuroxime: Antacids may decrease the serum concentration of Cefuroxime.  Management: Administer cefuroxime axetil at least 1 hour before or 2 hours after the administration of short-acting antacids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chenodiol: Aluminum Hydroxide may decrease the serum concentration of Chenodiol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloroquine: Antacids may decrease the serum concentration of Chloroquine.  Management: Separate the administration of antacids and chloroquine by at least 4 hours to minimize any potential negative impact of antacids on chloroquine bioavailability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholic Acid: Aluminum Hydroxide may decrease the absorption of Cholic Acid.  Management: Administer cholic acid at least 1 hour before or 4 to 6 hours after administration of any aluminum hydroxide-containing products to minimize the potential for a significant interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Citric Acid Derivatives: May increase the absorption of Aluminum Hydroxide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Oral): Antacids may decrease the bioavailability of Corticosteroids (Oral).  Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cysteamine (Systemic): Antacids may diminish the therapeutic effect of Cysteamine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: Antacids may decrease the serum concentration of Dabigatran Etexilate.  Management: Dabigatran etexilate Canadian product labeling recommends avoiding concomitant use with antacids for 24 hours after surgery. In other situations, administer dabigatran etexilate 2 hours prior to antacids. Monitor clinical response to dabigatran therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: Antacids may decrease the serum concentration of Dasatinib.  Management: Simultaneous administration of dasatinib and antacids should be avoided. Administer antacids 2 hours before or 2 hours after dasatinib.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: Aluminum Hydroxide may diminish the therapeutic effect of Deferasirox. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Polyvalent Cation Containing Products may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delavirdine: Antacids may decrease the serum concentration of Delavirdine.  Management: Separate doses of delavirdine and antacids by at least 1 hour. Monitor for decreased delavirdine therapeutic effects with this combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diacerein: Antacids may decrease the absorption of Diacerein. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dichlorphenamide: Laxatives may enhance the hypokalemic effect of Dichlorphenamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dolutegravir: Aluminum Hydroxide may decrease the serum concentration of Dolutegravir.  Management: Administer dolutegravir at least 2 hours before or 6 hours after oral aluminum hydroxide. Administer the dolutegravir/rilpivirine combination product at least 4 hours before or 6 hours after oral aluminum hydroxide.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxercalciferol: May enhance the hypermagnesemic effect of Magnesium Salts. Management: Consider using a non-magnesium-containing antacid or phosphate-binding product in patients also receiving doxercalciferol. If magnesium-containing products must be used with doxercalciferol, serum magnesium concentrations should be monitored closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eltrombopag: Polyvalent Cation Containing Products may decrease the serum concentration of Eltrombopag.  Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any polyvalent cation containing product.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elvitegravir: Antacids may decrease the serum concentration of Elvitegravir.  Management: Separate administration of aluminum and magnesium containing antacids and elvitegravir-containing products by at least 2 hours in order to minimize the risk for an interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: Serum Phosphate Level-Altering Agents may diminish the therapeutic effect of Erdafitinib.  Management: Avoid coadministration of serum phosphate level-altering agents with erdafitinib before initial dose increase period based on serum phosphate levels (Days 14 to 21).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erlotinib: Antacids may decrease the serum concentration of Erlotinib.  Management: Separate the administration of erlotinib and any antacid by several hours in order to minimize the risk of a significant interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ethambutol: Aluminum Hydroxide may decrease the serum concentration of Ethambutol.  Management: Avoid concurrent administration of ethambutol and aluminum hydroxide. If coadministration cannot be avoided administer ethambutol first and then wait at least 4 hours before administering aluminum hydroxide-containing products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexofenadine: Antacids may decrease the serum concentration of Fexofenadine.  Management: Separate the administration of fexofenadine and aluminum- or magnesium-containing antacids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosinopril: Antacids may decrease the serum concentration of Fosinopril.  Management: The US and Canadian fosinopril manufacturer labels recommend separating the doses of antacids and fosinopril by 2 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gabapentin: Aluminum Hydroxide may decrease the serum concentration of Gabapentin.  Management: Administer gabapentin at least 2 hours after administration of antacids containing aluminum hydroxide or magnesium hydroxide.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gefitinib: Antacids may decrease the serum concentration of Gefitinib.  Management: Administer gefitinib at least 6 hours before or 6 hours after administration of an antacid, and closely monitor clinical response to gefitinib.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyoscyamine: Antacids may decrease the serum concentration of Hyoscyamine.  Management: Administer immediate release and sublingual oral hyoscyamine before meals, and antacids after meals, when these agents are given in combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Infigratinib: Antacids may decrease serum concentrations of the active metabolite(s) of Infigratinib. Antacids may decrease the serum concentration of Infigratinib.  Management: Avoid coadministration of infigratinib with antacids or other gastric acid-lowering agents. If antacids cannot be avoided, administer infigratinib 2 hours before or after administration of antacids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iron Preparations: Antacids may decrease the absorption of Iron Preparations.  Management: No action is likely necessary for the majority of patients who only use antacids intermittently or occasionally. Consider separating doses of oral iron and antacids in patients who require chronic use of both agents and monitor for reduced iron efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoniazid: Antacids may decrease the absorption of Isoniazid. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: Antacids may decrease the serum concentration of Itraconazole. Antacids may increase the serum concentration of Itraconazole.  Management: Administer Sporanox brand itraconazole at least 2 hours before or 2 hours after administration of any antacids. Exposure to Tolsura brand itraconazole may be increased by antacids; consider itraconazole dose reduction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): Antacids may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer antacids at least 1 hour prior to, or 2 hours after, ketoconazole. Additionally, administer ketoconazole with an acidic beverage (eg, non-diet cola) and monitor patients closely for signs of inadequate clinical response to ketoconazole.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lanthanum: Antacids may diminish the therapeutic effect of Lanthanum.  Management: Administer antacid products at least 2 hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ledipasvir: Antacids may decrease the serum concentration of Ledipasvir.  Management: Separate the administration of ledipasvir and antacids by 4 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: Antacids may decrease the absorption of Levoketoconazole.  Management: Advise patients to take antacids at least 2 hours after taking levoketoconazole.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levonadifloxacin: Magnesium Salts may decrease the serum concentration of Levonadifloxacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levonadifloxacin: Antacids may decrease the serum concentration of Levonadifloxacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: Magnesium Salts may decrease the serum concentration of Levothyroxine.  Management: Separate administration of oral levothyroxine and oral magnesium salts by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mequitazine: Aluminum Hydroxide may decrease the absorption of Mequitazine.  Management: Administer mequitazine at least 2 hours before or 2 hours after administration of any aluminum hydroxide-containing products to minimize the potential for a significant interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mesalamine: Antacids may diminish the therapeutic effect of Mesalamine. Antacid-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Avoid concurrent administration of antacids with the Apriso brand of mesalamine extended-release capsules. The optimal duration of dose separation is unknown. Other mesalamine products do not contain this interaction warning.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methenamine: Antacids may diminish the therapeutic effect of Methenamine.  Management: Consider avoiding the concomitant use of medications that alkalinize the urine, such as antacids, and methenamine. Monitor for decreased therapeutic effects of methenamine if used concomitant with antacids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiSOPROStol: Antacids may enhance the adverse/toxic effect of MiSOPROStol. More specifically, concomitant use with magnesium-containing antacids may increase the risk of diarrhea.  Management: Avoid concomitant use of misoprostol and magnesium-containing antacids. In patients requiring antacid therapy, employ magnesium-free preparations. Monitor for increased adverse effects (e.g., diarrhea, dehydration).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Moxifloxacin (Systemic): Aluminum Hydroxide may decrease the absorption of Moxifloxacin (Systemic).  Management: Administer moxifloxacin at least 4 hours before or 8 hours after aluminum hydroxide.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May increase the serum concentration of Aluminum Hydroxide. Aluminum Hydroxide may decrease the serum concentration of Multivitamins/Fluoride (with ADE). Specifically, aluminum hydroxide may impair fluoride absorption. Management: Avoid administration of aluminum hydroxide within at least 1-2 hours of fluoride administration. In patients with severe renal dysfunction, consider avoiding this combination altogether.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May increase the serum concentration of Aluminum Hydroxide. Management: In patients with severe renal dysfunction, consider avoiding this combination of agents.  Administering agents at least 2 hours apart may help minimize the interaction(s). If combined, monitor for toxic effects of aluminum.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May increase the serum concentration of Aluminum Hydroxide. Specifically, vitamin C may enhance aluminum absorption. Management: In patients with severe renal dysfunction, consider avoiding this combination of agents.  Administering agents at least 2 hours apart may help minimize the interaction(s). If coadministered, monitor for toxic effects of aluminum.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate: Magnesium Hydroxide may decrease the serum concentration of Mycophenolate.  Management: Simultaneous administration of magnesium hydroxide antacids with the Myfortic brand of mycophenolic acid is specifically not recommended. Administer magnesium hydroxide at least 2 hours after a dose of the Cellcept brand of mycophenolate mofetil.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate: Aluminum Hydroxide may decrease the serum concentration of Mycophenolate.  Management: Simultaneous administration of aluminum hydroxide antacids with the Myfortic brand of mycophenolic acid is not recommended. Administrater aluminum hydroxide at least 2 hours after a dose of the Cellcept brand of mycophenolate mofetil.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neratinib: Antacids may decrease the serum concentration of Neratinib. Specifically, antacids may reduce neratinib absorption.  Management: Separate the administration of neratinib and antacids by giving neratinib at least 3 hours after the antacid.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents: Magnesium Salts may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilotinib: Antacids may decrease the serum concentration of Nilotinib.  Management: Separate the administration of nilotinib and any antacid by at least 2 hours whenever possible in order to minimize the risk of a significant interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirogacestat: Antacids may decrease the serum concentration of Nirogacestat.  Management: If acid-reducing therapy is required, separate nirogacestat administration from antacids by 2 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Octreotide: Antacids may decrease the serum concentration of Octreotide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: Antacids may decrease the serum concentration of PAZOPanib.  Management: Avoid the use of antacids in combination with pazopanib whenever possible. Separate doses by several hours if antacid treatment is considered necessary. The impact of dose separation has not been investigated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PenicillAMINE: Polyvalent Cation Containing Products may decrease the serum concentration of PenicillAMINE.  Management: Separate the administration of penicillamine and oral polyvalent cation containing products by at least 1 hour.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pexidartinib: Antacids may decrease the serum concentration of Pexidartinib.  Management: Administer pexidartinib at least 2 hours before or 2 hours after antacids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphate Supplements: Antacids may decrease the absorption of Phosphate Supplements.  Management: This applies only to oral phosphate administration. Separating administration of oral phosphate supplements from antacid administration by as long as possible may minimize the interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphate Supplements: Magnesium Salts may decrease the serum concentration of Phosphate Supplements.  Management: Administer oral phosphate supplements as far apart from the administration of an oral magnesium salt as possible to minimize the significance of this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Phosphate: Antacids may decrease the serum concentration of Potassium Phosphate.  Management: Consider separating administration of antacids and oral potassium phosphate by at least 2 hours to decrease risk of a significant interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNINE: Antacids may decrease the serum concentration of QuiNINE. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: Antacids may decrease the absorption of Quinolones. Of concern only with oral administration of quinolones.  Management: Avoid concurrent administration of quinolones and antacids to minimize the impact of this interaction. Recommendations for optimal dose separation vary by specific quinolone; see full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: Magnesium Salts may decrease the serum concentration of Quinolones.  Management: Administer oral quinolones several hours before (4 h for moxi/pe/spar/enox-, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome/pe/enox-, 3 h for gemi-, and 2 h for levo-, nor-, or ofloxacin or nalidixic acid) oral magnesium salts.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Raltegravir: Aluminum Hydroxide may decrease the serum concentration of Raltegravir.  Management: Avoid the use of oral / enteral aluminum hydroxide with raltegravir. No dose separation schedule has been established that adequately reduces the magnitude of interaction.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilpivirine: Antacids may decrease the serum concentration of Rilpivirine.  Management: Administer antacids at least 2 hours before or 4 hours after oral rilpivirine when used with most rilpivirine products. However, administer antacids at least 6 hours before or 4 hours after the rilpivirine/dolutegravir combination product.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Riociguat: Antacids may decrease the serum concentration of Riociguat.  Management: Separate the administration of antacids and riociguat by at least 1 hour in order to minimize any potential interaction. Monitor clinical response to riociguat more closely in patients using this combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rosuvastatin: Antacids may decrease the serum concentration of Rosuvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roxadustat: Polyvalent Cation Containing Products may decrease the serum concentration of Roxadustat.  Management: Administer roxadustat at least 1 hour after the administration of oral polyvalent cation containing products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: Antacids may decrease the serum concentration of Selpercatinib.  Management: Coadministration of selpercatinib and antacids should be avoided. If coadministration cannot be avoided, selpercatinib should be administered 2 hours before or 2 hours after antacids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Polystyrene Sulfonate: Laxatives (Magnesium Containing) may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. More specifically, concomitant use of sodium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of sodium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sotalol: Antacids may decrease the serum concentration of Sotalol.  Management: Avoid simultaneous administration of sotalol and antacids. Administer antacids 2 hours after sotalol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sotorasib: Antacids may decrease the serum concentration of Sotorasib.  Management: Avoid coadministration of sotorasib and antacids. If use of a gastric acid suppressing medication cannot be avoided, administer sotorasib 4 hours before or 10 hours after oral antacid administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: Antacids may decrease the serum concentration of Sparsentan.  Management: Administer sparsentan 2 hours before or 2 hours after antacids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Strontium Ranelate: Aluminum Hydroxide may decrease the serum concentration of Strontium Ranelate.  Management: Separate administration of strontium ranelate and aluminum hydroxide by at least 2 hours when possible, in order to minimize this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Strontium Ranelate: Magnesium Hydroxide may decrease the serum concentration of Strontium Ranelate.  Management: Separate administration of strontium ranelate and magnesium hydroxide by at least 2 hours when possible, in order to minimize this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sucralfate: Antacids may diminish the therapeutic effect of Sucralfate.  Management: Consider separating the administration of antacids and sucralfate by at least 30 minutes.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulpiride: Antacids may decrease the serum concentration of Sulpiride.  Management: Separate administration of antacids and sulpiride by at least 2 hours in order to minimize the impact of antacids on sulpiride absorption.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Aluminum Hydroxide may decrease the serum concentration of Tacrolimus (Systemic). Particularly, maximum concentration may decrease. Aluminum Hydroxide may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Magnesium Hydroxide may increase the serum concentration of Tacrolimus (Systemic). Magnesium Hydroxide may decrease the serum concentration of Tacrolimus (Systemic). Specifically, maximum concentration may decrease. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: Aluminum Hydroxide may decrease the absorption of Taurursodiol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: Antacids may decrease the absorption of Tetracyclines.  Management: Separate administration of antacids and oral tetracycline derivatives by several hours when possible to minimize the extent of this potential interaction. Monitor for decreased therapeutic effects of tetracyclines.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: Magnesium Salts may decrease the absorption of Tetracyclines. Only applicable to oral preparations of each agent.  Management: Avoid coadministration of oral magnesium salts and oral tetracyclines. If coadministration cannot be avoided, administer oral magnesium at least 2 hours before, or 4 hours after, oral tetracyclines. Monitor for decreased tetracycline therapeutic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trientine: Polyvalent Cation Containing Products may decrease the serum concentration of Trientine.  Management: Avoid concomitant use of trientine and polyvalent cations. If oral iron supplements are required, separate the administration by 2 hours. For other oral polyvalent cations, give trientine 1 hour before, or 1 to 2 hours after the polyvalent cation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Unithiol: May diminish the therapeutic effect of Polyvalent Cation Containing Products.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ursodiol: Aluminum Hydroxide may decrease the serum concentration of Ursodiol.  Management: Separate administration of ursodiol and aluminum-containing antacid products to prevent adsorption in the gastrointestinal tract.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Velpatasvir: Antacids may decrease the serum concentration of Velpatasvir.  Management: Separate administration of velpatasvir and antacids by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin D Analogs: May increase the serum concentration of Aluminum Hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations. Management: Consider avoiding chronic use of aluminum and aluminum-containing products in patients who are also taking active vitamin D analogs. If coadministered, monitor aluminum status and for signs and symptoms of aluminum-related toxicities.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F54814466"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Refer to individual monographs.</p></div>
<div class="block brc drugH1Div" id="F54814467"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Refer to individual monographs.</p></div>
<div class="block dic drugH1Div" id="F132553"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Almacone Double Strength suspension contains magnesium 165 mg and sodium 1 mg per 5 mL.</p>
<p style="text-indent:-2em;margin-left:2em;">Alamag Plus contains phenylalanine 2.6 mg and magnesium 83 mg per tablet</p>
<p style="text-indent:-2em;margin-left:2em;">Gelusil contains magnesium 85 mg per tablet.</p>
<p style="text-indent:-2em;margin-left:2em;">Maalox Advanced Maximum Strength suspension contains magnesium 145 mg and sodium 5 mg per 5 mL.</p>
<p style="text-indent:-2em;margin-left:2em;">Mi-Acid suspension contains magnesium 85 mg and sodium 1 mg per 5 mL.</p>
<p style="text-indent:-2em;margin-left:2em;">Mintox Plus contains magnesium 83.4 mg per tablet.</p>
<p style="text-indent:-2em;margin-left:2em;">Rulox suspension contains magnesium 85 mg per 5 mL.</p></div>
<div class="block pha drugH1Div" id="F26417991"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Aluminum hydroxide and magnesium hydroxide are antacids; simethicone is used to relieve symptoms of gas</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F132554"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Actonorm | Carelox plus | Maalox plus | Moxal plus | Mylanta ii | Neogastro plus | Simeco</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Aludrox | Aludrox ii | Faboacid | Factor ag antiacido | Gastroge | Mucalan a-g | Mylanta ii | Mylanta max | Mylanta plus | Pepsamar duo | Simecon antiacido | Simecon antiacido bebile | Suspension antiacida c/simeticona df</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Mylanta | Mylanta original</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Antanil-plus | Avlocid | Biocid plus | Entacyd plus | Flatameal | Gastrona | Magadrox plus | Neutral s | Peptacid | Pharmacid-plus | Seemacid plus</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Mylanta</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Gestid</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Almalox</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Alca luftal | Alcalone plus | Digeflex | Gastran | Gastrival composto | Gastrobem | Gastrobion | Gastrogel | Gastrogel fresh | Gastrol tc | Gelmax dim | Geltrat | Kolantyl dmp | Maalox | Magnazia | Mylanta plus | Pepsogel | Prodigest | Simeco plus | Stomaliv</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Gastrigel | Polygel | Viscid</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Ditopax | Gasopax | Maalox plus | Mylanta | Simeco plus</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Aced full | Acilax | Anforal | Antiacido | Calymag | Digel | Ditopax | Galac | Gastrigel | Gastritan | Gastrobutina | Gastrolife | Gastrosal | Gel ii mk | Hidropep | Hidrosin | Hidroxido de aluminio + hidroxido de magnesio + simeticona | Hidroxido de aluminio + magnesio + simeticona | Maalox plus | Magnelum compuesto | Magnemox | Metromag | Metromag ii | Mk doss | Multigel | Mylanta | Mylanta ct | Mylanta dos | Mylanta ii | Neutracid | Neutrogel | Pepsamar plus | Re hidroflux | Reflugax | Simetil | Sinacid | Vongel d.t.</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Paractol</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Acifar | Antalox | Carbomag | Cymagel | Digel | Diomal | Diomal plus | Ditopax | Fenacid | Gelnacid sm | Maalox plus | Mylanta | Troxin</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Alukron | Flatlive | Mylanta</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Acidipan | Alucon | Alumatrend | Loburna</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Gelosim</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Aluminium hydroxide/magnesium hydroxide/simethicone | Corasil | Peptica | Viscid</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Mylanta</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Maalox plus | Mylanta | Novasil plus</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Maalox plus | Simeco</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Alumag-s | Antad | Axcel eviline forte | Bf Maschew | Bio Gastal | Dimegel | Diovol Forte | Diovol plus | Eurogel | Eviline | Gelusil plus | Hydrosil | Lantacid | M A S | Maalox plus | Magal | Mylanta | Mylanta rs | S M A | Siloxogene | Simeco | Sinwell | Sma | Triloxane V | U Lanta | Vickmans Mas | Vida Meco | Walotab S | Welmagel | Zigatab</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Acitral | Aludonna d | Andrew actal plus | Anflat | Berlosid | Bufantacid | Carsida | Dexanta | Di-gel | Farmacrol forte | Formag | Gelusil mps | Gestabil | Gestamag | Hufamag plus | Indomag | Lagesil | Lambucid | Lexacrol | Maalox plus | Madrox | Magnidicon | Magtral | Mylacid | Mylanta | Neosanmag | Novamag | Plantacid | Polyanta | Polycrol | Riomag | Samtacid | Simeco | Tomaag | Trianta | Trofax | Ulcid | Ultilox</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Maalox plus</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Maalox plus</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Acidin mps | Acigel | Aciguard | Acinil | Almagel | Alucinol | Aluprogel | Anacid | Antacid | Antagit ds | Camagel mps | Capcid | Cardiocid | Centacid | Coolpep mps | Dab | Digiflux | Digusil mps | Diovol Forte | Disilox mps | Entasid MPS | Exocid | Gasmag | Gastromax | Gelona | Gelusil plus | Intacid mps | Klarcid | Lenocarb | Litacid | Logascid | Mac mps | Methicocid | Nucid | Nutracid | Peptica | Polycid | Polycrol Xpress Relief | Rabemac mps | Riogel s | Savocid | Siloxogene | Simeco | Ud alusil | Viscid | Zocid</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Acilox plus | Gasteredain plus | Gelocid plus</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Maalox plus</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Maalox plus | Moxal plus | Novagel plus</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Antagit ds | Beta cool | Centacid | Flatameal ds | Maalox plus | Nilacid | Pepgel | Peptica | Peptigo | Polycid plus | Siam | Siloxogene | Viscid</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Geron-g | Green-g | Jowigel | Maalox s | Mylanta | Mylanta ii | Rogel | Simeco | Varogel | Varomagel | Yudigel 2</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Carelox plus | Maalox plus | Medacid Plus | Moxal plus</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Actonorm | Diovol plus | Maalox plus</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Almagel neo | Manti | Protab</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Mylanta</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Almagel neo | Maalox plus | Protab</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Alka-gel complex | Alkagel complex | Ditopax | Espagel compuesto | Melbin | Mylanll | Neutraforte | Neutralin comp | Noax 3</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Almaxane | Almecon | Belcid forte | Dyna u | Eviline | Gastotac | Gastrorelief | Gelusil forte | Gelusil plus | Gestid | Hydrosil | Maalox plus | Mylanta | Mylanta ii | Povil | Zellox II</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Alumina, magnesium &amp; simethicone | Antabon | Belcid | Esilox | Gestid | Locid | Maalox plus | Neogastro plus | Pepsid | Riwod | Rulox plus</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Mylanta | Mylanta 11 | Mylanta heartburn relief | Mylanta p</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Acidor | Acidor extra rapid | Andrews sabor a menta | Calmacid | Hidrox. alum. + hidrox. mage. + simeti. | Hidrox. alum. + Hidrox. magne. + Simeti. | Maalox plus | Moxal plus | Mylanta ct | Mylanta dos | Mylanta ii | Neutracid | Peptinal | Phillips</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Alsium | Kremil s | Kremil S Extra Str | Maalox plus | Monnax | Mylanta | Mylanta rolltabs</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Alkagex | Almagel | Alucid mp | Alucone | Amgecon | Anacid | Antasil | Deacid | Demox | Dijex mp | Dijex mp mf | Filmacid | Gelusil plus | Geocone | Hosgel | Kemycone | Lecid | Lemagel | Lifcid | Magnicon | Manacid | Mylanta | Polycrol | Polysim plus | Rejex mp | Semosil | Siam | Sigel | Silocrol | Simeco | Simecrol | Stargel | Trisil plus</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Manti</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Antacid I | Gelusil | Maalox | Maalox multi symptom | Maalox plus | Maglox | Mylanta | Mylanta childrens | Simaal | Stratuscare antacid &amp; antigas</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Maalox plus</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Antiacid | Banflax antiacido | Emetan antiacido | Factor ag antiacido | Maalox plus | Mylanta | Salcedol</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Actonorm Gel | Maalox Plus | Medacid Plus</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Almagel neo | Almolox "york" | Alprogel | Nasigel cherry | Protab</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Medacid Plus | Moxal plus | Mylanta ii | Novagel plus | Rialox plus</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Allumag MPS | Eviline | Gelusil | Hydrosil | Zellox II</span>;</li>
<li>
<span class="countryCode">(SL)</span> <span class="country">Sierra Leone</span><span class="countrySeparator">: </span><span class="drugName">Antacid | Bgacid | Ezycid | Magacol | Miracid | Roxacid</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Admag | Almaxane | Alugas | Alutop | Amico-l | Amogin Otc | Antacia-sm | Antacil | Belcid | Bowa | Brygel-s | Burajel | Cophargel | Deacid plus | Diovol Forte | Droxyl | Estacid | Gasitone | Gaspec S | Gastrona | Gasxid | Gelusil mps | Herogel | Kenya | L-dacin | Maalox plus | Maccrol | Macsil | Mag 77 | Magnum | Magsenum d | Manosimet | Mar | Mylanta ii | Newgel DS | Silomed | Simagel | Simcomag | Stomac | Stomox | T.o.gel | Ulcegel | Ulco | V day milk | Welin | Ziga</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Alujel | Asidal | Simeco</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">A.m.d. | Ams | Antagel | Antagel ii | Gastracin | Gelgel | Hosgel | Lederscon | Macgel | Mylanta | Mylanta ii | Simelium | Sinwell | Ulwycon | Wecon | Weicon</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Almagel neo | Manti</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Antagit ds | Axcel eviline forte | Centacid | Maalox | Minto | Moxal plus</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Maalox plus | Mylanta plus | Pepsamar duo | Simeco plus</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Acifar | Ditosil | Flati cona | Maaloxil | Magnum | Mylanta | Mylantados | Mylantamil | Valmecon</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Almasane | Extra strength antigas | Hamigel s | Mylenfa | Phagelpagel</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Gelusil s | Lo-acid | Maalox plus</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Antagit ds | Digusil mps | Lo-acid | Nutrigel | Peptica | Polygel | Zellox II</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Neutragel</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aluminum-hydroxide-magnesium-hydroxide-and-simethicone-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Gelusil (aluminum hydroxide/magnesium hydroxide/simethicone) [prescribing information]. Sarasota, FL: WellSpring; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23629618">
<a name="23629618"></a>Lightdale JR, Gremse DA; Section on Gastroenterology, Hepatology, and Nutrition. Gastroesophageal reflux: management guidance for the pediatrician. <i>Pediatrics</i>. 2013;131(5):e1684-1695. doi:10.1542/peds.2013-0421<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aluminum-hydroxide-magnesium-hydroxide-and-simethicone-drug-information/abstract-text/23629618/pubmed" id="23629618" target="_blank">23629618</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Mag-AL Plus (aluminum hydroxide/magnesium hydroxide/simethicone) [prescribing information]. Greenville, SC: Pharmaceutical Associates Inc; received April 2019.</div>
</li>
<li>
<div class="reference">
                  Mag-AL Plus (aluminum hydroxide/magnesium hydroxide/simethicone) [prescribing information]. Greenville, SC: Pharmaceutical Associates Inc; January 2022.</div>
</li>
<li>
<div class="reference">
                  Mi-Acid Maximum Strength (aluminum hydroxide/magnesium hydroxide/simethicone) [prescribing information]. Livonia, MI: Major Pharmaceuticals; April 2018.</div>
</li>
<li>
<div class="reference">
                  Mi-Acid Regular Strength (aluminum hydroxide/magnesium hydroxide/simethicone) [prescribing information]. Livonia, MI: Major Pharmaceuticals; November 2018.</div>
</li>
<li>
<div class="reference">
                  Mintox Plus Tabs (aluminum hydroxide/magnesium hydroxide/simethicone) [prescribing information]. Livonia, MI: Major Pharmaceuticals; December 2017.</div>
</li>
<li>
<div class="reference">
                  Mylanta (aluminum hydroxide/magnesium hydroxide/simethicone) [prescribing information]. Westport, CT: Infirst Healthcare Inc; received February 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29470322">
<a name="29470322"></a>Rosen R, Vandenplas Y, Singendonk M, et al. Pediatric gastroesophageal reflux clinical practice guidelines: Joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). <i>J Pediatr Gastroenterol Nutr</i>. 2018;66(3):516-554. doi:10.1097/MPG.0000000000001889<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aluminum-hydroxide-magnesium-hydroxide-and-simethicone-drug-information/abstract-text/29470322/pubmed" id="29470322" target="_blank">29470322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aluminum-hydroxide-magnesium-hydroxide-and-simethicone-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1987526">
<a name="1987526"></a>Tsou VM, Young RM, Hart MH, Vanderhoof JA. Elevated plasma aluminum levels in normal infants receiving antacids containing aluminum. <i>Pediatrics</i>. 1991;87(2):148-151.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aluminum-hydroxide-magnesium-hydroxide-and-simethicone-drug-information/abstract-text/1987526/pubmed" id="1987526" target="_blank">1987526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1605980">
<a name="1605980"></a>Woodard-Knight L, Fudge A, Teubner J, Simmer K. Aluminium absorption and antacid therapy in infancy. <i>J Paediatr Child Health</i>. 1992;28(3):257-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aluminum-hydroxide-magnesium-hydroxide-and-simethicone-drug-information/abstract-text/1605980/pubmed" id="1605980" target="_blank">1605980</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aluminum-hydroxide-magnesium-hydroxide-and-simethicone-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8616 Version 388.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
